Lion Point Capital’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Lion Point Capital’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-601,579	Closed	-$2.53M	–	38
2023 Q1	$2.53M	Sell	601,579 -3,101,072	-84%	-$16.1M	1.04%	13
2022 Q4	$10.6M	Sell	3,702,651 -686,895	-16%	-$3.75M	1.51%	10
2022 Q3	$11.7M	Sell	4,389,546 -1,100,000	-20%	-$6.86M	2.57%	12
2022 Q2	$14.5M	Hold	5,489,546	–	–	1.65%	12
2022 Q1	$25.6M	Buy	5,489,546 +4,265,951	+349%	+$12.7M	5.95%	5
2021 Q4	$3.03M	Buy	+1,223,595	New	+$2.99M	0.81%	22

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Lion Point Capital's CTIC Position: Q2 2023 in Review

Lion Point Capital sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 601,579 shares — an estimated $2.53M sold.

Lion Point Capital first reported a position in CTIC in Q4 2021 and held it in 6 quarters. The position peaked at $25.6M in Q1 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Lion Point Capital reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Lion Point Capital sold 601,579 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $2.53M.
Lion Point Capital first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2021 and held it in 6 quarters.
Lion Point Capital's CTI BioPharma Corp. (DE) Common Stock position peaked at $25.6M in Q1 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Lion Point Capital's 13F filing for Q2 2023, filed 14 Aug 2023.